Publications by authors named "Heather Douangpanya"
Death receptor agonist therapies have exhibited limited clinical benefit to date. Investigations into why Apo2L/TRAIL and AMG 655 preclinical data were not predictive of clinical response revealed that coadministration of Apo2L/TRAIL with AMG 655 leads to increased antitumor activity in vitro and in vivo. The combination of Apo2L/TRAIL and AMG 655 results in enhanced signaling and can sensitize Apo2L/TRAIL-resistant cells.
View Article and Find Full Text PDFArticle Synopsis
- Bone metastases involve tumor cells interacting with the bone environment, promoting the formation of osteoclasts through RANK ligand (RANKL), leading to bone destruction and growth factor release.
- Inhibition of RANKL can block tumor-induced bone damage and decrease the tumor burden in models of breast cancer.
- Combining RANKL inhibition with rhApo2L/TRAIL treatment significantly reduces skeletal tumor burden more effectively than either treatment alone, highlighting a potential therapeutic approach for managing bone metastases.
Cancer presents a difficult challenge for oncologists, as there are few therapies that specifically target disease cells. Existing treatment strategies rely heavily on physical and chemical agents that nonspecifically affect DNA metabolism. To improve the effectiveness of these treatments, we have identified a new class of protein kinase inhibitor that targets a major DNA repair pathway.
View Article and Find Full Text PDF